Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) traded with a subtraction of -$5.33 to close at $146.36on Friday, a downside of -3.51 percent. An average of 497,763 shares of common stock have been traded in the last five days. There was a fall of -$5.45 in the past week, and it reached a new high 12 times over the past 12 months. The last 20 days have seen an average of 473,586 shares traded, while the 50-day average volume stands at 343,664.
MDGL stock has decreased by -17.82% in the last month. The company shares reached their 1-month lowest point of $143.75 on 09/26/23. With the stock rallying to its 52-week high on 05/01/23, shares of the company touched a low of $57.21 and a high of $322.67 in 52 weeks. It has reached a new high 9 times so far this year and lost -49.57% or -$142.36 in price. In spite of this, the price is down -54.64% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
MDGL stock investors should be aware that Madrigal Pharmaceuticals Inc (MDGL) stock had its last reported insider trading activity 212 days ago on Mar 01. In this transaction, the insider spent $1,372,081. Senior VP, Chief Pharma Dev., Waltermire Robert E., disposed of 5,000 shares at a price of $272.07 on Feb 28. The insider now owns more than $1,360,357 worth of shares. Prior to that, Director Levy Richard S went on to Sale 22,489 shares at $293.15 each on Jan 17. An amount of $6,592,686 was transacted.
Valuation Metrics
Madrigal Pharmaceuticals Inc (MDGL) has a trailing price-to-earnings (P/E) ratio of N/A for the broader industry. The stock’s beta is -0.65. Other valuation ratios to consider include the price-to-book (PB) ratio at 26.10.
Financial Health
The quick ratio of Madrigal Pharmaceuticals Inc for the three months ended June 29 was 3.02, and the current ratio was 3.02, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.96 and a total debt to equity ratio of 0.96 for the quarter ending June 29. Its gross profit as reported stood at $3.96 million compared to revenue of $293.57 million.
Earnings Surprise
For the three-month period that ended June 29, Madrigal Pharmaceuticals Inc had $99.25 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$85.8 million in the quarter, while revenues of -$76.9 million were grew 17.56%. The analyst consensus anticipated Madrigal Pharmaceuticals Inc’s latest quarter earnings to come in at -$4.58 per share, but it turned out to be -$4.69, a -2.40% surprise. For the quarter, EBITDA amounted to -$85.77 million. Shareholders own equity worth $18.47 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Madrigal Pharmaceuticals Inc (MDGL) price momentum. RSI 9-day as of the close on 28 September was 28.70%, suggesting the stock is oversold, with historical volatility in this time frame at 37.88%.
As of today, MDGL’s price is $150.19 -3.55% or -$5.45 from its 5-day moving average. MDGL is currently trading -17.84% lower than its 20-day SMA and -52.12% lower than its 100-day SMA. However, the stock’s current price level is -30.63% below the SMA50 and +132.68% above the SMA200.
The stochastic %K and %D were 12.65% and 11.39%, respectively, and the average true range (ATR) was 9.61. With the 14-day stochastic at 8.35% and the average true range at 9.37, the RSI (14) stands at 31.79%. The stock has reached -4.60 on the 9-day MACD Oscillator while the 14-day reading was at -12.27.
Analyst Ratings
Oppenheimer reiterated its an Outperform rating on Madrigal Pharmaceuticals Inc (NASDAQ: MDGL), but raised their price target to $170, indicating a potential price increase of 13.91% for the stock. The consensus rating for Madrigal Pharmaceuticals Inc (MDGL) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell MDGL, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 11 others rate it as a “buy”.
What is MDGL’s price target for the next 12 months?
Analysts predict a range of price targets between $224.00 and $410.00, with a median target of $330.50. Taking a look at these predictions, the average price target given by analysts for Madrigal Pharmaceuticals Inc (MDGL) stock is $326.83.
